Issues
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Articles
Anti-CD3 Monoclonal Antibody Treatment of Patients with CD3-Negative Tumors: A Phase IA/B Study1
Inhibition of 7,12-Dimethylbenz(a)anthracene-induced Tumors and DNA Adduct Formation in the Mammary Glands of Female Sprague-Dawley Rats by the Synthetic Organoselenium Compound, 1,4-Phenylenebis(methylene)selenocyanate1
Pharmacokinetics and Toxicity of Continuous Infusion (6S)-Folinic Acid and Bolus 5-Fluorouracil in Patients with Advanced Cancer1
Sustained Release Formulations of Luteinizing Hormone-releasing Hormone Antagonist SB-75 Inhibit Proliferation and Enhance Apoptotic Cell Death of Human Prostate Carcinoma (PC-82) in Male Nude Mice1
Radioimmunoscintigraphy of Head and Neck Cancer Using 99mTc-labeled Monoclonal Antibody E48 F(ab′)21
Metaphase and Interphase Cytogenetics with Alu-PCR-amplified Yeast Artificial Chromosome Clones Containing the BCR Gene and the Protooncogenes c-raf-1, c-fms, and c-erbB-21
Quantitation of Human Tumor-reactive Monoclonal Antibody 16.88 in the Circulation and Localization of 16.88 in Colorectal Metastatic Tumor Tissue Using Murine Antiidiotypic Antibodies
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds